Experienced in Hypophosphatasia (HPP)

Katsuhiro Kobayashi

Okayama, JP 
Experienced in Hypophosphatasia (HPP)
Okayama, JP 
OverviewLocationsClinical Research

Overview

Katsuhiro Kobayashi practices in Okayama, Japan. Kobayashi is rated as an Experienced expert by MediFind in the treatment of Hypophosphatasia (HPP). Their top areas of expertise are West Syndrome, Epilepsy, Epilepsy in Children, and Spasmus Nutans.

Their clinical research consists of co-authoring 124 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Hypophosphatasia (HPP).

Locations

Okayama, Japan
Other Locations
2 Chome, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)
A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)
Enrollment Status: Terminated
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drug: Soticlestat
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Adult Subjects With Dravet Syndrome (DS)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Adult Subjects With Dravet Syndrome (DS)
Enrollment Status: Completed
Publish Date: January 01, 2025
Intervention Type: Drug
Study Drug: Soticlestat
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Subjects With Lennox-Gastaut Syndrome (LGS)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Subjects With Lennox-Gastaut Syndrome (LGS)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drug: Soticlestat
Study Phase: Phase 3
A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in Community Settings
A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in Community Settings
Enrollment Status: Completed
Publish Date: September 14, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Multicenter, Open-label Study to Determine the Efficacy, Safety, and Pharmacokinetics of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in the Hospital or Emergency Room
A Phase 3, Multicenter, Open-label Study to Determine the Efficacy, Safety, and Pharmacokinetics of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in the Hospital or Emergency Room
Enrollment Status: Completed
Publish Date: July 31, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

124 Total Publications

Investigation of the relationship between 0.5-1200 Hz signal characteristics of cortical high-frequency oscillations and epileptogenicity through multivariate analysis.
Investigation of the relationship between 0.5-1200 Hz signal characteristics of cortical high-frequency oscillations and epileptogenicity through multivariate analysis.
Journal: Epilepsy & behavior reports
Published: March 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Kobayashi's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 31 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile